Dasatinib promotes the expansion of a therapeutically superior T-cell repertoire in response to dendritic cell vaccination against melanoma.
about
Trial watch: Dendritic cell-based anticancer therapyRationale for a Multimodality Strategy to Enhance the Efficacy of Dendritic Cell-Based Cancer Immunotherapy.Adjunct Strategies for Tuberculosis Vaccines: Modulating Key Immune Cell Regulatory Mechanisms to Potentiate VaccinationCombining immunotherapy with oncogene-targeted therapy: a new road for melanoma treatment.The induction of human myeloid derived suppressor cells through hepatic stellate cells is dose-dependently inhibited by the tyrosine kinase inhibitors nilotinib, dasatinib and sorafenib, but not sunitinib.Retroviral Replicating Vectors Deliver Cytosine Deaminase Leading to Targeted 5-Fluorouracil-Mediated Cytotoxicity in Multiple Human Cancer Types.Dendritic cell vaccines: A review of recent developments and their potential pediatric application.Combination strategies to enhance the potency of monocyte-derived dendritic cell-based cancer vaccines.Intratumoral delivery of mTORC2-deficient dendritic cells inhibits B16 melanoma growth by promoting CD8(+) effector T cell responses.Therapeutic efficacy of combined vaccination against tumor pericyte-associated antigens DLK1 and DLK2 in mice.The Yin and Yang of Tyrosine Kinase Inhibition During Experimental Polymicrobial Sepsis.Synergistic anti-tumor effects of dasatinib and dendritic cell vaccine on metastatic breast cancer in a mouse model.
P2860
Q27024047-6BFB1EC1-86D0-43E5-BA13-D015B8507D9EQ27686800-784BD422-5C16-41F1-ADFF-488713F8DD18Q28074536-92113DA5-DCBD-48E1-9DCB-8BA687F3A8D0Q35063621-EA8F3A3C-92B8-41AA-BDCD-BAA9FF1B4CA6Q35898395-5055FA81-23AD-42AA-ABB4-9F229038AEB1Q36602123-26F510B5-34DF-444B-A554-B86280D15688Q38849396-1984031C-B7A9-4796-B200-BE97C6F62E6DQ38948897-D0A08D3E-D6F0-424C-B695-3AF0D5886A46Q39546506-67456CC0-2FE2-4142-9854-EDFBAD303CD2Q52881532-1E482A00-21A9-4787-A6CA-B4E69C439123Q54109924-392A8E83-07FE-40B3-BC67-AB5BF060B0D7Q55075934-F0B9E705-FCEF-4430-BD6C-CB1EDC1B5A58
P2860
Dasatinib promotes the expansion of a therapeutically superior T-cell repertoire in response to dendritic cell vaccination against melanoma.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 2014
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Dasatinib promotes the expansi ...... vaccination against melanoma.
@en
Dasatinib promotes the expansi ...... vaccination against melanoma.
@nl
type
label
Dasatinib promotes the expansi ...... vaccination against melanoma.
@en
Dasatinib promotes the expansi ...... vaccination against melanoma.
@nl
prefLabel
Dasatinib promotes the expansi ...... vaccination against melanoma.
@en
Dasatinib promotes the expansi ...... vaccination against melanoma.
@nl
P2093
P2860
P356
P1433
P1476
Dasatinib promotes the expansi ...... vaccination against melanoma.
@en
P2093
Anamika Bose
Hussein Tawbi
Jennifer L Taylor
John M Kirkwood
P2860
P304
P356
10.4161/ONCI.27589
P577
2014-01-01T00:00:00Z